Hospital Universitario De Canarias — Clinical Trial Site

86 Registered trials

30 Currently recruiting

Organisation

Hospital Universitario De Canarias

Location

San Cristobal De La Laguna, Spain

Identifier

ORG-100048773

Address

Carretera Ofra S/N, 38320, Spain

Departments

#2242; Reumatología
#3403 - Reumatología
3403: Reumatología
Alergología
Alergology
Allergology
Allergy
Cardiology
Endocrinology
Gastroenterology
Gynecology and Obstetrics
Hematología
Hematology
Hematology and Hemotherapy
infectious diseases
Infectious diseases service
Infectious Diseases Unit
Medical Oncology
Medicina Interna
N/A
Nephrology
Neurología
Oftalmologia
Oncologia
Oncologia Medica
Oncology
Oncology Department
Oncology Service
Pediatric
Pediatric Oncology
Pediatric Oncology and Haematology Unit
Reumatología
Rheumatology
Rheumatology Department
Servicio de Endocrinologia
Servicio de enfermedades Infecciosas
Servicio de Hematología
Servicio de Oncologia
Servicio de Oncología Médica
Servicio de Reumatología
Urology

Clinical trials at this site (86)

Search interface

A clinical trial to evaluate efficacy, safety and cost-efficacy of gene analysis strategy in a population at risk of cardiovascular disease … Ended

2023-509418-12-00 Patients at risk of cardiovascular disease susceptible 6 2024-06-05
Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with M… Ended

2022-502975-45-00 Metastatic leiomyosarcoma 5 2023-12-12
Phase 3 study to evaluate two regimens of ianalumab on top of standardof- care therapy in patients with systemic lupus erythematosus (SIRIUS… Ended

2023-508498-97-00 Systemic Lupus Erythematosus 5 2023-02-03
Extended VRD plus Early Rescue vs Isatuximab-VRD vs Isatuximab-VIberdomide-D for NDMM patients who are candidates for ASCT Ended

2024-517008-12-00 Newly-diagnosed multiple myeloma (NDMM) 5 2022-10-14
A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combin… Ended

2023-503467-41-00 Relapsed or Refractory Multiple Myeloma 5 2022-10-12
Multicenter, phase II, national and open-label study to evaluate Iberdomide-dexamethasone alone or in combination with standard MM treatment… Ended

2024-518870-15-00 Multiple Myeloma 4 2022-10-03
Study of efficacy, safety and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus n… Ended

2023-508559-37-00 Lupus nephritis 5 2022-07-14
A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can… Ended

2023-503826-37-00 Unresectable locally-advanced or metastatic HER2+ breas 5 2022-02-11
An open label, multicenter, phase I/II study of belantamab mafodotin in combination with Kd for the treatment of relapsed myeloma patients, … Ended

2024-517006-28-00 Multiple myeloma 9 2021-11-23
Trial of different schemes of PM14 alone and in combination with radiotherapy in soft tissue sarcomas and other solid tumors Ended

2024-519893-38-00 Soft tissue sarcomas and other solid tumors 9 2021-11-23
EMBER-3 A Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Participants with ER+, HER… Ended

2023-506786-63-00 Breast Cancer 5 2021-09-30
Randomized clinical trial assessing the value of Beta-Blockers and Antiplatelet Agents in patients with Spontaneous Coronary Artery Dissecti… Ended

2024-516039-28-00 Spontaneous Coronary Artery Dissection. 6 2021-09-28
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive… Ended

2023-503568-18-00 Early human epidermal growth factor receptor 2 (HER2) p 5 2021-04-13
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant versus Placebo Plus Palbociclib and Fulvestrant in… Ended

2023-505812-39-00 HR+/HER2-Negative Locally Advanced or Metastatic Breast 5 2020-08-28
Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma Ended

2024-512704-20-00 Unresectable and/or metastatic soft-tissue sarcoma afte 4 2020-06-22
Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2… Ended

2023-505042-25-00 Locally advanced (inoperable) or metastatic HR+/HER2 br 5 2020-05-05
Palbociclib for HR positive Isolated Local or Regional Recurrence of Breast Cancer Ended

2024-510776-20-00 Female or male patients with histologically confirmed H 5 2019-10-25
Study for patients with Primary Hyperoxaluria to evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection Ended

2024-512260-54-00 Primary Hyperoxaluria 5 2019-08-20
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 hormone receptor (HR)-positive, HER2-negative, early br 5 2019-05-22
A Phase 3 Study to compare how effective and safe DCC-2618 is versus sunitinib in patients with GIST who have been treated previously with i… Ended

2024-513277-52-00 Patients with Advanced Gastrointestinal Stromal Tumors 5 2019-05-20
Testing a new targeted therapy trastuzumab deruxtecan (DS-8201a) against ado-trastuzumab emtansine (T-DM1) for patients with advanced stage … Ended

2024-511204-16-00 Metastatic breast cancer 5 2019-01-23
Study to evaluate the efficacy of 3 different treatments, followed by maintenance treatment, in older adult patients, between 65 and 80 year… Ended

2024-516905-22-00 Multiple myeloma 5 2018-10-22